Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NASH AMPK Exercise Dosing (AMPED) Trial (AMPED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04987879
Recruitment Status : Not yet recruiting
First Posted : August 3, 2021
Last Update Posted : August 3, 2021
Sponsor:
Information provided by (Responsible Party):
Jonathan Stine, Milton S. Hershey Medical Center

Brief Summary:

There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD.

While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.


Condition or disease Intervention/treatment Phase
NAFLD Behavioral: Exercise Not Applicable

Detailed Description:
The mechanism explaining how exercise training benefits patients with NAFLD and NASH is unclear. The AMPK pathway may be responsible for the benefits seen with exercise training because: 1) AMPK has a liver-specific role in hepatic de novo lipogenesis and fatty acid oxidation, 2) AMPK activity is abnormally low in NAFLD and 3) NAFLD animal models demonstrate exercise changes the liver-specific AMPK pathway, leading to less liver fat accumulation by reducing lipogenesis and increasing fatty acid oxidation (This has not been studied in patients). Importantly, exercise-induced AMPK activation appears to be dose dependent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: NASH AMPK Exercise Dosing (AMPED) Trial
Estimated Study Start Date : December 2021
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Exercise Arm 1
Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min/wk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
Behavioral: Exercise
Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
Other Name: Physical activity

Experimental: Exercise Arm 2
Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 1,000 MET-min/wk for 3-5 days per week, 30-60 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
Behavioral: Exercise
Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
Other Name: Physical activity

No Intervention: Standard of Care
This group will receive best NASH clinical practices counseling at baseline and end-of-trial in accordance with NAFLD clinical practice guidelines and be reinforced by handouts from the American Liver Foundation.



Primary Outcome Measures :
  1. Change in liver fat [ Time Frame: 16 weeks ]
    Degree of liver fat change as measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) across different doses of exercise in patients with NASH.


Secondary Outcome Measures :
  1. Hip/waist circumference [ Time Frame: 16 weeks ]
    change in Hip/waist circumference

  2. Body mass index [ Time Frame: 16 weeks ]
    change in body mass index

  3. change in body composition [ Time Frame: 16 weeks ]
    change in body composition as measured by Dual-energy X-ray absorptiometry (DXA scan) across different doses of exercise in patients with NASH.

  4. Insulin [ Time Frame: 16 weeks ]
    change in insulin

  5. Hemoglobin A1c [ Time Frame: 16 weeks ]
    change in Hemoglobin A1c

  6. change in cholesterol and triglycerides levels (dyslipidemia) [ Time Frame: 16 weeks ]
    change in cholesterol and triglycerides levels (dyslipidemia) as measured by clinical labs.

  7. Interleukin-6 [ Time Frame: 16 weeks ]
    change in Interleukin-6

  8. c-reactive protein [ Time Frame: 16 weeks ]
    change in c-reactive protein

  9. Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score [ Time Frame: 16 weeks ]

    change in NAFLD Fibrosis Score which estimates amount of scarring in the liver based on several laboratory tests.

    NAFLD Score Correlated Fibrosis Severity < -1.455 F0-F2

    -1.455 - 0.675 Indeterminant score > 0.675 F3-F4 Fibrosis Severity Scale

    F0 = no fibrosis F1 = mild fibrosis F2 = moderate fibrosis F3 = severe fibrosis F4 = cirrhosis


  10. Enhance liver fibrosis (ELF) test [ Time Frame: 16 weeks ]
    change in Enhance liver fibrosis (ELF) test

  11. TIMP-1 [ Time Frame: 16 weeks ]
    change in TIMP-1

  12. ProC3 [ Time Frame: 16 weeks ]
    change in ProC3

  13. Adiponectin [ Time Frame: 16 weeks ]
    change in Adiponectin

  14. Fibroblast Growth Factor (FGF) 21 [ Time Frame: 16 weeks ]
    change in Fibroblast Growth Factor (FGF) 21

  15. Change in stiffness of the liver [ Time Frame: 16 weeks ]
    Change in stiffness of the liver as measured by the technique of transient elastography, a non-invasive test to stage the severity of liver disease.

  16. Liver glycogen [ Time Frame: 16 weeks ]
    change in liver glycogen

  17. Liver ATP [ Time Frame: 16 weeks ]
    change in liver ATP



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-69 years
  • Sedentary [<90 min/wk of exercise identified by the Get Active Questionnaire (GAQ)
  • BMI >30kg/m2
  • Liver biopsy within six months prior to enrollment showing:

    • NASH defined by NASH Clinical Research Network (CRN) histology scoring system (NAS) >4 and MRI-PDFF >5% and;
    • Liver fibrosis stage 1-3

Exclusion Criteria:

  • Active cardiac symptoms
  • Body mass index (BMI) >45kg/m2
  • Cancer that is active
  • Inability to walk >2 blocks
  • Institutionalized/prisoner
  • Other liver disease
  • Pregnancy
  • Secondary hepatic steatosis
  • Severe comorbidities
  • AUDIT-C questionnaire identified significant alcohol use
  • Substance abuse/active smoking
  • Uncontrolled diabetes (changes in drug dosing over previous three months or A1c >9%)
  • GAQ response indicates exercise may be unsafe.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04987879


Contacts
Layout table for location contacts
Contact: Gloriany Rivas, BA 7175310003 ext 320223 grivas@pennstatehealth.psu.edu

Sponsors and Collaborators
Milton S. Hershey Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Jonathan G Stine Milton S. Hershey Medical Center
Layout table for additonal information
Responsible Party: Jonathan Stine, Director of Research, Penn State Liver Center, Assosiate Professor of Medicine and Public Health Sciences, Milton S. Hershey Medical Center
ClinicalTrials.gov Identifier: NCT04987879    
Other Study ID Numbers: STUDY00018280
First Posted: August 3, 2021    Key Record Dates
Last Update Posted: August 3, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No